Delving into the Latest Updates on EBV-Tscm Cytotoxic T Cells(University Hospital, Basel) with Synapse

Overview

Basic Info

Drug Type

T-lymphocyte cell therapy

Synonyms-

Target-

Action-

Mechanism

Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Universitätsspital Basel

Active Organization-

Inactive Organization-

Drug Highest Phase-

First Approval Date-

Regulation-

Login to view timeline

In this multi-center open-label, non-randomized phase I/II intervention study three consecutive doses of donor-derived EBV Tscm-CTLs will be administered to 10 patients with treatment-refractory EBV lymphoma, diseases or PTLDs. EBV Tscm-CTLs will derive from hematopoietic cell transplant (HCT) or third-party donors.

Start Date01 Nov 2026

Sponsor / Collaborator

Universitätsspital Basel

100 Clinical Results associated with EBV-Tscm Cytotoxic T Cells(University Hospital, Basel)

Login to view more data

100 Translational Medicine associated with EBV-Tscm Cytotoxic T Cells(University Hospital, Basel)

Login to view more data

100 Patents (Medical) associated with EBV-Tscm Cytotoxic T Cells(University Hospital, Basel)

Login to view more data

100 Deals associated with EBV-Tscm Cytotoxic T Cells(University Hospital, Basel)

Login to view more data